(Q36326225)

13 August 2017

1 reference

title

Cryptococcal disease and HIV infection (English)

1 reference

13 August 2017

Laura Waters

1

1 reference

13 August 2017

Mark Nelson

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

15

1 reference

13 August 2017

page(s)

2633-2644

1 reference

Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

The spectrum of MRI findings in CNS cryptococcosis in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Primary prophylaxis for cryptococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Cessation of secondary prophylaxis in patients with cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.15.2633

10.1517/14656566.6.15.2633

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference